LISTING OF THE CLAIMS

No claim amendment is made by this reply. The claims are listed here for Examiner's convenience.

(Previously Presented) A method of inhibiting human stearoyl-CoA desaturase
(hSCD) activity comprising contacting a source of hSCD with a compound of formula (I):

wherein:

x and y are each independently 1;

W is -N(R1)C(O)N(R1)-;

V is -C(O)-;

each R1 is independently selected from the group consisting of hydrogen,

C₁-C₁₂alkyl, C₂-C₁₂hydroxyalkyl, C₄-C₁₂cycloalkylalkyl and C₇-C₁₉aralkyl;

 $R^2 \ is \ selected \ from \ the \ group \ consisting \ of \ C_1\text{-}C_{12} alkyl, \ C_2\text{-}C_{12} alkenyl, \ C_2\text{-}C_{12} alkenyl, \ C_2\text{-}C_{12} alkenyl, \ C_2\text{-}C_{12} cycloalkyl, \ C_3\text{-}C_{12} cycloalkyl, \ C_3\text{-}C_$

or \mathbb{R}^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R3 is phenyl or naphthalene:

R⁴, R⁵ and R⁸ are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R¹³)₅:

 R^7 , R^7 a, R^8 , R^{8a} , R^9 , R^{9a} , R^{10} , and R^{10a} are each independently selected from hydrogen or C_1 - C_3 alkyl;

and

each R¹³ is independently selected from hydrogen or C₁-C₆alkyl;
a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

 (Previously Presented) A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I):

wherein:

x and v are each independently 1:

W is -N(R1)C(O)N(R1)-:

V is -C(O)-:

each R1 is independently selected from the group consisting of hydrogen.

C1-C12alkyl, C2-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R3 is phenyl or naphthalene:

 R^4 , R^5 and R^6 are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R^{15});

 R^7 , R^{79} , R^8 , R^{8a} , R^9 , R^{9a} , R^{10} , and R^{10a} are each independently selected from hydrogen or C_1 - C_3 alkyl;

and

each R¹³ is independently selected from hydrogen or C₁-C₅alkyl;
a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

- (Original) The method of Claim 2 wherein the mammal is a human.
- 4. (Previously Presented) The method of Claim 3 wherein the disease or condition is selected from the group consisting of Type II diabetes, fatty liver, non-alcoholic steatohepatitis, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, acne, and metabolic syndrome and any combination of these.
- (Original) The method of Claim 4 wherein the disease or condition is Type II diabetes.
 - (Original) The method of Claim 4 wherein the disease or condition is obesity.
- 7. (Original) The method of Claim 4 wherein the disease or condition is metabolic syndrome.
 - (Original) The method of Claim 4 wherein the disease or condition is fatty liver.
- (Original) The method of Claim 4 wherein the disease or condition is nonalcoholic steatohepatitis.
 - (Withdrawn) A compound of formula (IIa):

$$R^{2} \longrightarrow R^{6} \longrightarrow R^{10} \times R^{10} \times R^{7} \times R^{7a} \longrightarrow R^{2} \times R^{8a} \times R^{8a$$

wherein:

No.: 10/566,193 Docket No.: 17243/003001

x and y are each independently 1;

R¹ is selected from the group consisting of hydrogen, C₁-C₁₂alkyl,

Co-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;

R2 is selected from the group consisting of C7-C12alkyl, C3-C12alkenyl,

C7-C12hydroxyalkyl, C2-C12alkoxyalkyl, C3-C12hydroxyalkenyl, C3-C12cycloalkyl,

C₄-C₁₂cycloalkylalkyl, C₁₃-C₁₉aralkyl, C₁-C₁₂heteroaryl, C₃-C₁₂heterocyclylalkyl,

 C_3 - C_{12} heterocyclyl, and C_3 - C_{12} heteroarylalkyl, provided that R^2 is not pyrazinyl, pyridinonyl, pyrrolidinonyl or imidazolyl:

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

 $R^3 \ is \ selected from the group consisting of $C_3-C_{12}alkyl, $C_3-C_{12}alkenyl,$$$ $C_3-C_{12}hydroxyalkyl, $C_3-C_{12}hydroxyalkenyl, $C_3-C_{12}alkoxyalkyl, $C_3-C_{12}cycloalkyl,$$$$ $C_4-C_{12}cycloalkylalkyl, aryl, $C_7-C_{12}aralkyl, $C_3-C_{12}heterocyclyl, $C_3-C_{12}heterocyclylalkyl, $C_1-C_{12}heteroaryl and $C_3-C_{12}heteroarylalkyl;$$$$$

or R³ is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 R^4 , R^6 and R^6 are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or $-N(R^{13})_2$;

 R^7 , R^{7_9} , R^8 , R^{8_8} , R^9 , R^{9_8} , R^{10} and R^{108} are each independently selected from hydrogen or C_1 - C_3 alkyl;

and

each R¹³ is independently selected from hydrogen or C₁-C₆alkyl;
a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

11. (Withdrawn) The compound of Claim 10 wherein: x and y are each independently 1:

R¹ is selected from the group consisting of hydrogen, C₁-C₁-alkyl.

C2-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;

 $R^2 \hspace{0.5mm}\text{is selected from the group consisting of $C_7\text{-}C_{12}$alkyl, $C_3\text{-}C_{12}$alkenyl,}$

 $C_7-C_{12}\text{hydroxyalkyl},\ C_2-C_{12}\text{alkoxyalkyl},\ C_3-C_{12}\text{hydroxyalkenyl},\ C_3-C_{12}\text{cycloalkyl},\ C_4-C_{12}\text{cycloalkylalkyl},\ C_{13}-C_{19}\text{aralkyl},\ C_{1}-C_{12}\text{heteroaryl},\ C_3-C_{12}\text{heterocyclylalkyl},\ C_3-C_{12}\text{heteroarylalkyl},\ provided that R^2 is not pyrazinyl, pyridinonyl, pyrrolidinonyl or imidazolyl;}$

 $R^3 \ is selected from the group consisting of $C_3-C_{12}alkyl, $C_3-C_{12}alkenyl,$$$ $C_{12}-C_{12}hydroxyalkyl, $C_3-C_{12}hydroxyalkenyl, $C_3-C_{12}alkoxyalkyl, $C_3-C_{12}cycloalkyl,$$$ $C_4-C_{12}cycloalkylalkyl, aryl, $C_7-C_{19}aralkyl, $C_3-C_{12}heterocyclyl, $C_3-C_{12}heterocyclylalkyl, $C_1-C_{12}heteroaryl and $C_3-C_{12}heteroarylalkyl;$$$$

 R^4 , R^5 and R^6 are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or $-N(R^{13})_2$;

 $R^7,\,R^{7a},\,R^8,\,R^{8a},\,R^9,\,R^{9a},\,R^{10}$ and R^{10a} are each independently selected from hydrogen or C_1 - C_3 alkyl; and

each R^{13} is independently selected from hydrogen or $C_1\text{-}C_6$ alkyl.

(Withdrawn) The compound of Claim 11 wherein:
 x and y are each 1;

 R^1 is selected from the group consisting of hydrogen or C_1 - C_{12} alkyl; R^2 is selected from the group consisting of C_2 - C_{12} alkyl, C_3 - C_{12} alkenyl,

 $C_{3}-C_{12}cycloalkyl,\ C_{4}-C_{12}cycloalkylalkyl,\ C_{13}-C_{19}aralkyl,\ C_{1}-C_{12}heteroaryl,\ C_{3}-C_{12}heterocyclylalkyl and\ C_{7}-C_{19}heteroarylalkyl;$

 $R^3 is selected from the group consisting of C_3-C_{12} alkyl, C_3-C_{12} cycloalkyl, \\ C_4-C_{12} cycloalkylalkyl, aryl, C_7-C_{19} aralkyl, C_3-C_{12} heterocyclyl, C_3-C_{12} heterocyclylalkyl, C_1-C_{12} heteroaryl and C_3-C_{12} heteroarylalkyl; \\$

 $R^4, R^6 \ and \ R^6 \ are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or <math>-N(R^{15})_{2}$;

 $R^7, R^{7a}, R^8, R^{8a}, R^9, R^{9a}, R^{10} \ and \ R^{10a} \ are each independently selected from hydrogen or <math>C_1$ - C_3 alkyl; and

each R¹³ is independently selected from hydrogen or C₁-C₆alkyl.

(Withdrawn) The compound of Claim 12 wherein:
 R² is C₃-C₁₂cycloalkyl or C₄-C₁₂cycloalkylalkyl;
 R³ is selected from the group consisting of C₇-C₁₂cycloalkyl or

C4-C12cycloalkylalkyl;

 R^4 , R^5 and R^6 are each hydrogen; and R^7 , R^{7a} , R^8 , R^{8a} , R^9 , R^{9a} , R^{10} and R^{10a} are each hydrogen or C_1 - C_3 alkyl.

14. (Withdrawn) The compound of Claim 13 wherein:

R² is C₃-C₁₂cycloalkyl; and

R³ is C₃-C₁₂cycloalkyl.

- (Withdrawn) The compound of Claim 14, namely, Cyclohexanecarboxylic acid [6-(4-cyclohexanecarbonyl-piperazin-1-yl)pyridin-3-yl]amide.
- 16. (Withdrawn) A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 10.
- (Withdrawn) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 10.
 - (Withdrawn) A compound of formula (IIb):

$$R^{2} \xrightarrow{R^{4}} R^{4} \xrightarrow{R^{5}_{R} 10a} R^{10} R^{7} R^{7a}$$

$$R^{2} \xrightarrow{N} R^{6} R^{9a} R^{8a} R^{8a}$$

$$R^{2} \xrightarrow{R^{9}_{R} R^{9}_{R} R^{8a}} R^{8a}$$
(IIIb)

wherein:

x and y are each independently 1;

R¹ is selected from the group consisting of hydrogen, C₁-C₁₂alkyl.

C2-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_{12}\text{alkyl}, C_2\text{-}C_{12}\text{alkenyl}, \\ C_2\text{-}C_{12}\text{hydroxyalkyl}, C_2\text{-}C_{12}\text{hydroxyalkenyl}, C_1\text{-}C_{6}\text{alkoxy}, C_3\text{-}C_{12}\text{alkoxyalkyl}, C_3\text{-}C_{12}\text{cycloalkyl}, \\ C_4\text{-}C_{12}\text{cycloalkylalkyl}, C_7\text{-}C_{19}\text{aralkyl}, C_3\text{-}C_{12}\text{ heterocyclyl}, C_3\text{-}C_{12}\text{heterocyclylalkyl}, \\ C_4\text{-}C_{12}\text$

C1-C12heteroaryl and C3-C12heteroarylalkyl;

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

 R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, $C_1\text{-}C_6\text{alkyl}$, $C_1\text{-}C_6\text{trihaloalky}$, $C_1\text{-}C_6\text{alkyl}$, $N(R^{12})_2$, -OC(O)R^{12}, -C(O)OR^{12}, -S(O)_2N(R^{12})_2, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl, provided that R^3 is not phenyl substituted with optionally substituted thienvi:

 R^4 , R^6 and R^6 are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R^{18})₂;

 R^7 , R^{7a} , R^8 , R^{8a} , R^9 , R^{8a} , R^{10} , and R^{10a} are each independently selected from hydrogen or C₁-C₃alkyl:

and

each R 12 is independently selected from hydrogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, aryl or aralkyl; and

each R¹³ is independently selected from hydrogen or C₁-C₆alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

19. (Withdrawn) The compound of Claim 18 wherein:

x and v are each independently 1:

R¹ is selected from the group consisting of hydrogen, C₁-C₁₂alkyl,

C2-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;

 R^2 is selected from the group consisting of C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, C_2 - C_{12} hydroxyalkyl, C_2 - C_{12} hydroxyalkenyl, C_1 - C_0 alkoxy, C_3 - C_{12} alkoxyalkyl, C_3 - C_{12} cycloalkyl, C_4 - C_1 2cycloalkylalkyl, C_7 - C_1 9aralkyl, C_3 - C_1 2 heterocyclyl, C_3 - C_1 2heterocyclylalkyl, C_7 - C_9 3heteroaryl and C_9 - C_9 3heteroarylalkyl.

 R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, $C_1\text{-}C_6\text{alkyl},\ C_1\text{-}C_6\text{trihaloalkyl},\ C_1\text{-}C_6\text{trihaloalkyl},\ C_1\text{-}C_6\text{dikylsulfonyl},\ -N(R^{12})_2,\ -OC(O)R^{12},\ -C(O)OR^{12},\ -S(O)_2N(R^{12})_2,\ cycloalkyl,\ heterocyclyl,$ heteroaryl and heteroarylcycloalkyl, provided that R^3 is not phenyl substituted with optionally substituted thienyl;

 R^4 , R^6 and R^6 are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or $-N(R^{13})_2$;

 $R^7, R^{7a}, R^8, R^{8a}, R^9, R^{8a}, R^{10}, \text{ and } R^{10a} \text{ are each independently selected from } \\ \text{hydrogen or } C_1\text{-}C_3\text{alkyl, or }$

 R^{10} and R^{10a} together form an oxo group and the remaining R^7 , R^{7a} , R^8 , R^{8a} , R^9 and R^{9a} are each hydrogen:

each R^{12} is independently selected from hydrogen, C_1 - C_e alkyl, C_3 - C_e cycloalkyl, aryl or aralkyl; and

each R13 is independently selected from hydrogen or C1-C6alkyl.

20. (Withdrawn) The compound of Claim 19 wherein:

x and y are each 1;

R1 is hydrogen or C1-C12alkyl;

R² is selected from the group consisting of C₁-C₁₂alkyl, C₂-C₁₂alkenyl,

 $C_{2}-C_{12}\text{hydroxyalkyl}, C_{2}-C_{12}\text{hydroxyalkenyl}, C_{1}-C_{6}\text{alkoxy}, C_{3}-C_{12}\text{alkoxyalkyl}, C_{3}-C_{12}\text{cycloalkyl}, \\ C_{4}-C_{12}\text{cycloalkylalkyl}, C_{7}-C_{19}\text{aralkyl}, C_{3}-C_{12}\text{ heterocyclyl}, C_{3}-C_{12}\text{heterocyclylalkyl}, \\ C_{1}-C_{12}\text{heteroaryl} \text{ and } C_{3}-C_{12}\text{heteroarylalkyl}; \\$

 $$\rm R^3$ is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, $\rm C_1\text{-}C_6$ likyl, $\rm C_1\text{-}C_6$ trihaloalky, $\rm C_1\text{-}C_6$ likylsulfonyl, -N(R^12)_2, -OC(O)R^12, -C(O)OR^12, -S(O)_2N(R^12)_2, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl, provided that $\rm R^3$ is not phenyl substituted with optionally substituted thienyl.

R4, R5 and R6 are each hydrogen;

R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each hydrogen; or

 R^{10} and R^{10a} together form an oxo group and the remaining R^7 , R^{7a} , R^8 , R^{8a} , R^9 and R^{8a} are each hydrogen; and

 $\mbox{ each } R^{12} \mbox{ is independently selected from hydrogen, } C_{\tau^*} C_{\theta} \mbox{ellkyl, } C_{3^*} C_{\varepsilon} \mbox{cycloalkyl,} \\ \mbox{aryl or aralkyl.}$

21. (Withdrawn) The compound of Claim 20 wherein:

R2 is C1-C12alkyl; and

 R^3 is phenyl optionally substituted by one or more substituents selected from halo, C_1 - C_6 alkyl, C_1 - C_6 trihaloalkyl and C_1 - C_6 trihaloalkoxy.

22. (Withdrawn) The compound of Claim 21 selected from the group consisting of the following:

Docket No.: 17243/003001

4-Methylpentanoic acid {6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide;

Hexanoic acid {6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide;

Heptanoic acid {6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide;

Heptanoic acid {6-[4-(2,5-dichlorobenzoyl)piperazin-1-yl]pyridin-3-yl}amide; and

Hexanoic acid {6-[4-(2,5-dichlorobenzoyl)piperazin-1-yl]pyridin-3-yl}amide.

- 23. (Withdrawn) The compound of Claim 20 wherein:
 - R2 is C3-C12cvcloalkyl; and

 R^3 is phenyl optionally substituted by one or more substituents selected from halo, C_1 - C_8 elkyl, C_1 - C_8 trihaloalkyl and C_1 - C_8 trihaloalkoxy.

- (Withdrawn) The compound of Claim 23, namely, Cyclohexanecarboxylic acid {6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide.
 - 25. (Withdrawn) The compound of Claim 20 wherein:

R² is C₇-C₁₂aralkyl optionally substituted by one or more substituents selected from halo, C₁-C₆alkyl, C₁-C₆trihaloalkyl and C₁-C₆trihaloalkyxy; and

 $R^3 \ \text{is phenyl optionally substituted by one or more substituents selected from halo, $C_1 - C_8$ trihaloalkyl and $C_1 - C_9$ trihaloalkyl.}$

- 26. (Withdrawn) The compound of Claim 25 selected from the group consisting of the following:
- $3- Phenyl- {\it N-\{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl\} propionamide;}\\$
- 4-Phenyl-N-(6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}butyramide; and
- $\textit{N-} \{6-[2-Oxo-4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl\}-4-phenylbutyramide.$
- 27. (Withdrawn) A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 18.

 (Withdrawn) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 18.

(Withdrawn) The compound of formula (III):

wherein:

x and y are each independently 1;

 V_a is -C(O)-, -C(S)-, -C(O)N(R¹)-, -C(S)N(R¹)-, -C(O)O-, -C(S)O-, -S(O)_C(where t is 1 or 2) or -S(O)N(R¹)- (where t is 1 or 2):

each R¹ is independently selected from the group consisting of hydrogen, C₁-C₁-alkvl. C₂-C₂-hydroxvalkvl. C₂-C₃-cycloalkylalkyl and C₂-C₃-aralkvl:

 R^2 is selected from the group consisting of C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, C_2 - C_{12} hydroxyalkyl, C_2 - C_{12} hydroxyalkenyl, C_1 - C_0 alkoxy, C_3 - C_1 2alkoxyalkyl, C_3 - C_1 2cycloalkyl, C_3 - C_1 2beterocyclyl, C_3 - C_1 2heterocyclylalkyl, C_3 - C_1 2heteroaryl and C_3 - C_1 2heteroarylalkyl, C_1 - C_1 2heteroaryl and C_3 - C_1 3heteroarylalkyl;

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

 $R^{3} \ is \ selected \ from \ the \ group \ consisting \ of \ C_{1}\text{-}C_{12} alkyl, \ C_{2}\text{-}C_{12} alkenyl, \\ C_{2}\text{-}C_{12} hydroxyalkyl, \ C_{3}\text{-}C_{12} hydroxyalkenyl, \ C_{2}\text{-}C_{12} alkoxyalkyl, \ C_{3}\text{-}C_{12} cycloalkyl, \\ C_{4}\text{-}C_{12} cycloalkylalkyl, \ aryl, \ C_{7}\text{-}C_{19} aralkyl, \ C_{3}\text{-}C_{12} heterocyclyl, \ C_{3}\text{-}C_{12} heterocyclylalkyl, \\ C_{1}\text{-}C_{12} heteroaryl \ and \ C_{3}\text{-}C_{12} heteroarylalkyl; \\ \end{cases}$

or R³ is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R⁴, R⁵ and R⁶ are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R¹³)₂;

R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from

Docket No.: 17243/003001

hydrogen or C₁-C₃alkyl;

ar

each R¹³ is independently selected from hydrogen or C₁-C₆alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

30. (Withdrawn) The compound of Claim 29 wherein:

x and y are each independently 1;

 V_a is -C(O)- or -C(S)-;

R¹ is selected from the group consisting of hydrogen, C₁-C₁₂alkyl,

C2-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_{12}\text{alkyl}, C_2\text{-}C_{12}\text{alkenyl}, \\ C_2\text{-}C_{12}\text{hydroxyalkyl}, C_2\text{-}C_{12}\text{hydroxyalkenyl}, C_1\text{-}C_6\text{alkoxy}, C_3\text{-}C_{12}\text{alkoxyalkyl}, C_3\text{-}C_{12}\text{cycloalkyl}, \\ C_4\text{-}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{19}\text{aralkyl}, C_3\text{-}C_{12}\text{ heterocyclyl}, C_3\text{-}C_{12}\text{heterocyclylalkyl}, \\ C_1\text{-}C_1\text{-}\text{heteroaryl} \text{ and } C_3\text{-}C_1\text{-}\text{heteroarylalkyl}; \\ C_1\text{-}C_1\text{-}\text{heteroaryl} \text{ and } C_3\text{-}C_1\text{-}\text{heteroarylalkyl}; \\ \\$

 $R^3 \text{ is selected from the group consisting of } C_1\text{-}C_12\text{alkyl}, C_2\text{-}C_12\text{alkenyl}, \\ C_2\text{-}C_{12}\text{hydroxyalkyl}, C_2\text{-}C_{12}\text{hydroxyalkenyl}, C_2\text{-}C_{12}\text{alkoxyalkyl}, C_3\text{-}C_{12}\text{cycloalkyl}, \\ C_4\text{-}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{19}\text{aralkyl}, C_3\text{-}C_{12}\text{heterocyclyl}, C_3\text{-}C_{12}\text{heterocyclylalkyl}, \\ C_4\text{-}C_4\text{-heteroaryl} \text{ and } C_3\text{-}C_4\text{-heteroarylalkyl}. \\ C_4\text{-}C_4\text{-heteroaryl} \text{ and } C_3\text{-}C_4\text{-heteroarylalkyl}. \\$

 R^4 , R^5 and R^6 are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or $-N(R^{13})_2$;

 $R^7, R^{7o}, R^8, R^{8o}, R^9, R^{9a}, R^{10}, \text{ and } R^{10a} \text{ are each independently selected from hydrogen or } C_1-C_9 \text{alkyl}; \text{ and}$

each R13 is independently selected from hydrogen or C1-C6alkyl.

31. (Withdrawn) The compound of Claim 30 wherein:

x and y are each 1;

 V_a is -C(O)-;

R1 is hydrogen or C1-C12alkyl;

 $R^2 \ is \ selected \ from \ the \ group \ consisting \ of \ C_1-C_{12} alkyl, \ C_2-C_{12} alkenyl,$ $C_2-C_{12} hydroxyalkyl, \ C_2-C_{12} hydroxyalkenyl, \ C_1-C_0 alkoxy, \ C_3-C_{12} alkoxyalkyl, \ C_3-C_{12} cycloalkyl,$ $C_3-C_{12} cycloalkyl, aryl, \ C_1-C_{19} aralkyl, \ C_3-C_{12} \ heterocyclyl, \ C_3-C_{12} heterocyclyl alkyl,$ $C_3-C_{12} cycloalkyl, \ aryl, \ C_1-C_1 aralkyl, \ C_3-C_{12} \ heterocyclyl, \ C_3-C_{12} heterocyclyl alkyl,$

 C_1 - C_{12} heteroaryl and C_3 - C_{12} heteroarylalkyl;

 R^3 is naphthyl or phenyl, each optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, $C_1\text{-}C_6$ alkyl, $C_1\text{-}C_6$ trihaloalkyl, $C_1\text{-}C_6$ trihaloalkoxy, $C_1\text{-}C_6$

 R^4 , R^5 and R^6 are each hydrogen; R^7 , R^{7a} , R^8 , R^8 , R^8 , R^{9} , R^{10} , and R^{10a} are each hydrogen; and each R^{12} is independently selected from hydrogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, aryl or aralkyl.

32. (Withdrawn) The compound of Claim 31 wherein:

 $R^2 \text{ is } C_1\text{-}C_{12}\text{alkyl or } C_7\text{-}C_{12}\text{aralkyl optionally substituted by one or more substituents selected from the group consisting of halo, $C_1\text{-}C_6\text{alkyl}$, $C_1\text{-}C_5\text{trihaloalkyl}$ and $C_1\text{-}C_6\text{trihaloalkoxy}$.}$

 R^3 is naphthyl or phenyl, each optionally substituted by one or more substituents selected from the group consisting of halo, C_1 - C_0 alkyl, C_1 - C_0 trihaloalkyl and C_1 - C_0 trihaloalkoxy.

33. (Withdrawn) The compound of Claim 32 selected from the group consisting of the following:

Pentane-1-sulfonic acid {6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridin-3-yl]amide; Butane-1-sulfonic acid {6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridin-3-yl]amide; Hexane-1-sulfonic acid {6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridin-3-yl]amide; Pentane-1-sulfonic acid {6-[4-(2-bromobenzoyl)piperazin-1-yl]pyridin-3-yl]amide; Hexane-1-sulfonic acid {6-[4-(2,5-dichlorobenzoyl)-piperazin-1-yl]pyridin-3-yl]amide; Pentane-1-sulfonic acid {6-[4-(2,5-dichlorobenzoyl)-piperazin-1-yl]pyridin-3-yl]amide; Hexane-1-sulfonic acid {6-[4-(aphthalene-1-carbonyl)-piperazin-1-yl]pyridin-3-yl]amide; Pentane-1-sulfonic acid {6-[4-(naphthalene-1-carbonyl)-piperazin-1-yl]pyridin-3-yl]amide; and 3-Phenylpropane-1-sulfonic acid {6-[4-(2-trifluoromethyl-benzoyl)piperazin-1-yl]pyridin-3-yl]amide; pylamide.

 $34. \qquad \text{(Withdrawn) The compound of Claim 31 wherein:} \\ R^2 \text{ is } C_{4}\text{-}C_{12}\text{cycloalkylalkyl}, C_{7}\text{-}C_{19}\text{aralkyl}, C_{3}\text{-}C_{12}\text{heterocyclylalkyl} \text{ or } C_{3}\text{-}C_{12}\text{heteroarylalkyl};}$

R3 is naphthyl or phenyl, each optionally substituted by one or more substituents

selected from the group consisting of halo, C1-C6alkyl, C1-C6trihaloalkyl and C1-C6trihaloalkoxy.

- 35. (Withdrawn) A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 29.
- (Withdrawn) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 29.
 - 37. (Previously Presented) The compound of formula (IV):

wherein:

x and v are each independently 1:

V_a is -C(O)-:

each R¹ is independently selected from the group consisting of hydrogen,

C1-C12alkyl, C2-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;

 $R^2 is selected from the group consisting of C_{r}-C_{12}alkyl, C_2-C_{12}alkenyl, \\ C_{2}-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_3-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, \\ C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12} heterocyclyl, C_3-C_{12}heterocyclylalkyl, \\ C_{4}-C_{4}heteroaryl and C_{5}-C_{4}heteroarylalkyl; \\ C_{4}-C_{5}heteroaryl and C_{5}-C_{5}heteroarylalkyl; \\ C_{5}-C_{5}heteroaryl and C_{5}-C_{5}heteroarylalkyl; \\ C_{5}-C_{5}heteroarylalkyl, \\ C_{5}-C_{5}heteroarylalk$

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

R3 is phenyl or naphthalene;

R4, R5 and R6 are each independently selected from hydrogen, bromo, fluoro,

chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R13)2;

 R^7 , R^{7a} , R^8 , R^{8a} , R^9 , R^{9e} , R^{10} , and R^{10a} are each independently selected from hydrogen or C₁-C₂alkyl: and

each R¹⁸ is independently selected from hydrogen or C₁-C₈alkyl;
a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

(Previously Presented) The compound of Claim 37 wherein:
 x and y are each independently 1;

V_a is -C(O)-;

each R1 is independently selected from the group consisting of hydrogen,

C1-C12alkyl, C2-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;

 $R^2 \text{ is selected from the group consisting of $C_1\text{-}C_{12}\text{alklyl}$, $C_2\text{-}C_{12}\text{alkenyl}$, $C_2\text{-}C_{12}\text{hydroxyalkyl}$, $C_3\text{-}C_{12}\text{alkenyl}$, $C_3\text{-}C_{12}\text{alkenyl}$, $C_3\text{-}C_{12}\text{alkenyl}$, $C_3\text{-}C_{12}\text{cycloalkyl}$, $C_3\text{-}C_{12}\text{cycloalkyl}$, aryl, $C_7\text{-}C_{19}\text{aralkyl}$, $C_3\text{-}C_{12}$ heterocyclyl, $C_3\text{-}C_{12}$ heterocyclylalkyl, $C_3\text{-}C_{12}\text{-}heteroaryl and $C_3\text{-}C_3\text{-}heteroarylalkyl}$.}$

R3 is phenyl or naphthalene;

 R^4 , R^6 and R^6 are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R^{15})₂:

 $R^7, R^{7a}, R^8, R^{8a}, R^9, R^{9a}, R^{10}, \ and \ R^{10a} \ are each independently selected from hydrogen or C_1-C_3alkyl; and$

each R13 is independently selected from hydrogen or C1-C6alkyl.

(Previously Presented) The compound of Claim 38 wherein:

x and y are each 1;

V_o is -C(O)-:

each R1 is independently hydrogen or C1-C6alkyl;

R2 is selected from the group consisting of C1-C12alkyl, C2-C12alkenyl,

C2-C12hydroxyalkyl, C2-C12hydroxyalkenyl, C3-C12alkoxyalkyl, C3-C12cycloalkyl,

 $C_4 - C_{12} cycloalkylalkyl, \ aryl, \ C_7 - C_{19} aralkyl, \ C_3 - C_{12} \ heterocyclyl_i \ C_3 - C_{12} heterocyclylalkyl,$

C1-C12heteroaryl and C3-C12heteroarylalkyl;

R3 is phenyl or naphthalene;

Docket No.: 17243/003001

 R^4 , R^5 and R^6 are each hydrogen; R^7 , R^{7a} , R^9 , R^{8a} , R^9 , R^{9o} , R^{10} , and R^{10a} are each hydrogen; and each R^{12} is independently selected from hydrogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, arvl or aralkyl.

40. (Previously Presented) The compound of Claim 39 wherein: $R^2 \text{ is } C_1\text{-}C_{12} \text{alkyl or } C_7\text{-}C_{12} \text{aralkyl optionally substituted by one or more substituents selected from the group consisting of halo, $C_1\text{-}C_6 \text{alkyl}$, $C_7\text{-}C_6 \text{trihaloalkyl}$ and $C_7\text{-}C_6 \text{trihaloalkoxy}$; and $C_7\text{-}C_6 \text{-trihaloalkoxy}$; and $C_7\text{-}C_8 \text{-trihaloalkoxy}$; and $C_7\text{$

R3 is phenyl or naphthalene.

- 41. (Withdrawn) The compound of Claim 40 wherein R3 is C3-C12cycloalkyl.
- 42. (Withdrawn) The compound of Claim 41 selected from the group consisting of the following:
- 1-[6-(4-Cyclohexanecarbonylpiperazin-1-yl)pyridin-3-yl]-3-pentylurea; and 1-[6-(4-Cyclopentanecarbonylpiperazin-1-yl)pyridin-3-yl]-3-pentylurea.
- $\label{eq:43.43} \textbf{ (Original) The compound of Claim 40 wherein R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6 alkyl, C_1-C_6 trihaloalkyl and C_1-C_6 trihaloalkoxy.}$
- 44. (Original) The compound of Claim 43 selected from the group consisting of the following:
- 1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea;
- 1-Butyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yi]-pyridin-3-yl}urea;
- 1-Phenethyl-3-(6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yllpyridin-3-yllurea:
- 1-Benzyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; and
- 1-(4-Fluorobenzyl)-3-{6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridin-3-yl}urea.
- 45. (Withdrawn) The compound of Claim 40 wherein R³ is piperidinyl optionally substituted by C₁-C_nalkyl or C₂-C₁-aralkyl, wherein the C₂-C₁-aralkyl group is optionally

substituted by one or more substituents selected from the group consisting of halo, C_1 - C_0 alkyl, C_1 - C_0 trihaloalkvl and C_1 - C_0 trihaloalkvv.

- 46. (Withdrawn) The compound of Claim 45, namely, 1-{6-{4-(1-Benzylpiperidine-4-carbonyl)piperazin-1-yll-pyridin-3-yl}-3-pentylurea.
- (Withdrawn) The compound of Claim 40 wherein R³ is pyridinyl optionally substituted by one or more substituents selected from the group consisting of halo or C₁-C₆alkyl.
- 48. (Withdrawn) The compound of Claim 47 selected from the group consisting of the following:

1-Pentyl-3-{6-[4-(pyridine-2-carbonyl)piperazin-1-yl]-pyridin-3-yl}urea; and 1-Pentyl-3-{6-[4-(pyridine-4-carbonyl)piperazin-1-yl]-pyridin-3-yl}urea.

- 49. (Original) A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 37.
- (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 37.
 - (Withdrawn) The compound of formula (V):

$$R^{2}-W_{a}-V_{a}-V_{a}-V_{a}-V_{a}-R^{5}R^{10a}R^{70a}R^{70a}R^{7a}-V_{a}-R^{3}$$

wherein:

x and y are each independently 1;

Wa is -O-, -N(R1)- or -S(O)+ (where t is 0, 1 or 2);

 $\label{eq:Value} V_a \text{ is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(S)N(R^1)-, -C(O)O-, -C(S)O-, -S(O)_{l^2}(where \ t \ is \ 1 \ or \ 2) \ or \ -S(O)_{l^2}(R^1)- \ (where \ t \ is \ 1 \ or \ 2);$

each R¹ is independently selected from the group consisting of hydrogen,

 C_1 - C_{12} alkyl, C_2 - C_{12} hydroxyalkyl, C_4 - C_{12} cycloalkylalkyl and C_7 - C_{19} aralkyl;

 R^2 is selected from the group consisting of C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl,

 $C_2\text{-}C_{12}\text{hydroxyalkyl},\ C_2\text{-}C_{12}\text{hydroxyalkenyl},\ C_3\text{-}C_{12}\text{alkoxyalkyl},\ C_3\text{-}C_{12}\text{cycloalkyl},$

 C_4 - C_{12} cycloalkylalkyl, aryl, C_7 - C_{19} aralkyl, C_3 - C_{12} heterocyclyl, C_3 - C_{12} heterocyclylalkyl, C_3 - C_{12} heteroaryl and C_4 - C_{12} heteroarylalkyl;

or R² is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

 $R^3 \ is \ selected from the group consisting of $C_1-C_{12}alkyl$, $C_2-C_{12}alkenyl$, $C_2-C_{12}hydroxyalkyl$, $C_2-C_{12}hydroxyalkenyl$, $C_2-C_{12}alkoxyalkyl$, $C_2-C_{12}cycloalkyl$, $C_3-C_{12}cycloalkyl$, $C_3-C_{12}cycloalkyl$, aryl$, $C_7-C_{19}aralkyl$, $C_3-C_{12}heterocyclyl$, $C_3-C_{12}heterocyclylalkyl$, $C_1-C_{12}heteroaryl$ and $C_3-C_{12}heteroarylalkyl$;} \label{eq:Reconstruction}$

or R³ is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 $R^4, R^6 \ \text{and} \ R^6 \ \text{are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or <math>-N(R^{15})_{2i}$

 $R^7,\,R^{7a},\,R^8,\,R^{8a},\,R^9,\,R^{9a},\,R^{10},\,\text{and}\,\,R^{10a}\,\text{are each independently selected from hydrogen or}\,\,C_1-C_3\text{alkyl};$

and

each R^{13} is independently selected from hydrogen or $C_1\text{-}C_6$ alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

52. (Withdrawn) The compound of Claim 51 wherein:

x and y are each independently 1;

W_a is -O-, -N(R¹)- or -S(O)_r- (where t is 0, 1 or 2);

 $V_s \text{ is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(S)N(R^1)-, -C(O)O-, -S(O)-(where t is 1 or 2)} \\ \text{or -S(O),N(R^1)- (where t is 1 or 2);} \\$

each R1 is independently selected from the group consisting of hydrogen,

C₁-C₁₂alkyl, C₂-C₁₂hydroxyalkyl, C₄-C₁₂cycloalkylalkyl and C₇-C₁₉aralkyl;

 R^2 is selected from the group consisting of C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, C_2 - C_{12} hydroxyalkyl, C_3 - C_{12} alkenyl, C_3 - C_{12} alkoxyalkyl, C_3 - C_{12} cycloalkyl, C_3 - C_{12} cycloalkylalkyl, aryl, C_7 - C_{19} aralkyl, C_3 - C_{12} heterocyclyl, C_3 - C_{12} heterocyclylalkyl, C_3 - C_{12} heteroaryl and C_3 - C_3 -heteroarylalkyl.

 $R^3 \ is \ selected \ from \ the \ group \ consisting \ of \ C_1\text{-}C_{12} alkyl, \ C_2\text{-}C_{12} alkenyl, \\ C_2\text{-}C_{12} hydroxyalkyl, \ C_2\text{-}C_{12} hydroxyalkenyl, \ C_2\text{-}C_{12} alkoxyalkyl, \ C_3\text{-}C_{12} cycloalkyl, \\ C_4\text{-}C_{12} cycloalkylalkyl, \ aryl, \ C_7\text{-}C_{19} aralkyl, \ C_3\text{-}C_{12} heterocyclylalkyl, \\ C_1\text{-}C_{12} heteroaryl \ and \ C_3\text{-}C_{12} heteroarylalkyl; \\ C_1\text{-}C_{12} heteroaryl \ and \ C_3\text{-}C_{12} heteroarylalkyl; \\ C_1\text{-}C_{12} heteroarylalkyl, \ c_3\text{-}C_{12} heteroarylalkyl, \$

 R^4 , R^5 and R^6 are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or $-N(R^{13})_z$;

 $R^7,\,R^{7a},\,R^8,\,R^{9a},\,R^9,\,R^{9a},\,R^{10},\,and\,\,R^{10a}\,are\,\,each\,\,independently\,\,selected\,\,from\,\,hydrogen\,\,or\,\,C_1-C_3alkyl;\,and$

each R13 is independently selected from hydrogen or C1-C6alkyl.

53. (Withdrawn) The compound of Claim 52 wherein:

x and y are each 1;

W_o is -O-:

Va is -C(O)- or -C(S)-:

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_{12} \text{alkyl}, C_2\text{-}C_{12} \text{alkenyl}, \\ C_2\text{-}C_{12} \text{hydroxyalkyl}, C_2\text{-}C_{12} \text{hydroxyalkenyl}, C_3\text{-}C_{12} \text{alkoxyalkyl}, C_3\text{-}C_{12} \text{cycloalkyl}, \\ C_4\text{-}C_{12} \text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{19} \text{aralkyl}, C_3\text{-}C_{12} \text{ heterocyclyl}, C_3\text{-}C_{12} \text{heterocyclylalkyl}, \\ C_4\text{-}C_{12} \text{-}\text{tycheteroaryl} \text{ and } C_3\text{-}C_{12} \text{heteroarylalkyl}; \\ C_4\text{-}C_{12} \text{-}\text{tycheteroarylalkyl}; \\ C_4\text{-}C_{12} \text{-}\text{tycheteroarylalky$

 $R^3 \ is \ selected \ from \ the \ group \ consisting \ of \ C_3-C_{12} alkyl, \ C_3-C_{12} alkenyl, \\ C_3-C_{12} \ hydroxyalkyl, \ C_3-C_{12} \ hydroxyalkenyl, \ C_3-C_{12} alkoxy, \ C_3-C_{12} alkoxyalkyl, \ C_3-C_{12} \ colored \ kyl, \\ C_4-C_{12} \ cycloalkylalkyl, \ aryl, \ C_7-C_{19} \ aralkyl, \ C_3-C_{12} \ heteroacylalkyl, \ C_3-C_{12} \ heteroacylalkyl, \ argument \ and \ C_3-C_{12} \ heteroacylalkyl; \ colored \ colored$

 R^4 , R^5 and R^6 are each hydrogen; and R^7 , R^{7a} , R^8 , R^{8a} , R^9 , R^{9a} , R^{10} , and R^{10a} are each hydrogen.

54. (Withdrawn) The compound of Claim 53 wherein:

V₂ is -C(O)-:

R2 is selected from the group consisting of C1-C12alkyl, C3-C12cycloalkyl,

 C_4 - C_{12} cycloaikylalkyl, aryl, C_7 - C_{19} aralkyl, C_3 - C_{12} heterocyclyl, C_3 - C_{12} heterocyclylalkyl, C_4 - C_{19} heteroaryl and C_3 - C_{12} heteroarylalkyl; and

 $R^3 is selected from the group consisting of C_3-C_{12} cycloalkyl, C_4-C_{12} cycloalkylalkyl,\\ aryl, C_7-C_{19} aralkyl, C_3-C_{12} heterocyclyl, C_3-C_{12} heterocyclylalkyl, C_1-C_{12} heteroaryl and C_3-C_{12} heteroarylalkyl.$

55. (Withdrawn) The compound of Claim 52 wherein:

x and y are each 1;

 W_a is $-N(R^1)$ -;

 V_a is -C(O)- or -C(S)-;

R1 is hydrogen or C1-C6alkyl;

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_{12} \text{alkyl}, C_2\text{-}C_{12} \text{alkenyl}, \\ C_2\text{-}C_{12} \text{hydroxyalkyl}, C_2\text{-}C_{12} \text{hydroxyalkyl}, C_3\text{-}C_{12} \text{alkoxyalkyl}, C_3\text{-}C_{12} \text{cycloalkyl}. \\$

 C_4 - C_{12} cycloalkylalkyl, aryl, C_7 - C_{19} aralkyl, C_3 - C_{12} heterocyclyl, C_3 - C_{12} heterocyclylalkyl, C_4 - C_{19} heteroaryl and C_7 - C_{19} heteroarylalkyl;

 R^3 is selected from the group consisting of $C_3\text{-}C_{12}$ alkyl, $C_3\text{-}C_{12}$ alkenyl, $C_3\text{-}C_{12}\text{-}hydroxyalkyl, C_3\text{-}C_{12}\text{-}hydroxyalkenyl, } C_3\text{-}C_{12}\text{-}alkoxy, C_3\text{-}C_{12}\text{-}alkoxyalkyl, } C_3\text{-}C_{12}\text{-}ctolakyl, \\ C_4\text{-}C_{12}\text{-}cycloalkylalkyl, aryl, } C_7\text{-}C_{19}\text{-}aralkyl, } C_3\text{-}C_{12}\text{-}heterocyclyl, } C_3\text{-}C_{12}\text{-}heterocyclylalkyl, } C_1\text{-}C_{12}\text{-}heteroaryl and } C_3\text{-}C_{12}\text{-}heteroarylalkyl; }$

R4, R5 and R6 are each hydrogen; and

R⁷, R^{7a}, R⁸, R^{8a}, R⁹, R^{9a}, R¹⁰, and R^{10a} are each hydrogen.

56. (Withdrawn) The compound of Claim 55 wherein:

V_a is -C(O)-;

R² is selected from the group consisting of C₁-C₁₂alkyl, C₃-C₁₂cycloalkyl,

 C_4 - C_{12} cycloaikylalkyl, aryl, C_7 - C_{19} aralkyl, C_3 - C_{12} heterocyclyl, C_3 - C_{12} heterocyclylalkyl, C_4 - C_{12} heteroaryl and C_3 - C_{12} heteroarylalkyl; and

 $R^3 is selected from the group consisting of C_3-C_{12} cycloalkyl, C_4-C_{12} cycloalkylalkyl, aryl, C_7-C_{19} aralkyl, C_3-C_{12} heterocyclyl, C_3-C_{12} heterocyclylalkyl, C_1-C_{12} heteroaryl and C_3-C_{12} heteroarylalkyl. \\$

57. (Withdrawn) The compound of Claim 52 wherein: x and y are each 1;

Docket No.: 17243/003001

 W_a is $-S(O)_t$ (where t is 0, 1 or 2);

Va is -C(O)- or -C(S)-;

R² is selected from the group consisting of C₁-C₁₂alkyl, C₂-C₁₂alkenyl,

C2-C12hydroxyalkyl, C2-C12hydroxyalkenyl, C3-C12alkoxyalkyl, C3-C12cycloalkyl,

 $C_4-C_{12} \\ \text{cycloalkylalkyl, aryl, } C_7-C_{19} \\ \text{aralkyl, } C_3-C_{12} \text{ heterocyclyl, } C_3-C_{12} \\ \text{heterocyclylalkyl, } \\ C_{12} \\ \text{heterocyclylalkyl, } \\ C_{13} \\ \text{heterocyclylalkyl, } \\ C_{12} \\ \text{heterocyclylalkyl, } \\ C_{13} \\ \text{heterocyclylalkyl, } \\ C_{12} \\ \text{heterocyclylalkyl, } \\ C_{13} \\ \text{heterocyclylalkyl, } \\ C_{14} \\ \text{heterocyclylalkyl, } \\ C_{15} \\ \text{heterocyclylalkyl, } \\ C_{15}$

C₁-C₁₂heteroaryl and C₃-C₁₂heteroarylalkyl;

 $R^3 \ is \ selected \ from \ the \ group \ consisting \ of \ C_3-C_{12} alkyl, \ C_3-C_{12} alkenyl, \\ C_3-C_{12} \ hydroxyalkyl, \ C_3-C_{12} \ hydroxyalkenyl, \ C_3-C_{12} alkoxy, \ C_3-C_{12} alkoxyalkyl, \ C_3-C_{12} \ colored \ kyl, \\ C_4-C_{12} \ cycloalkylalkyl, \ aryl, \ C_7-C_{19} \ aralkyl, \ C_3-C_{12} \ heterocyclyl, \ C_3-C_{12} \ heterocyclylalkyl, \ C_1-C_{12} \ heteroaryl \ and \ C_3-C_{12} \ heteroarylalkyl;$

R4. R5 and R6 are each hydrogen; and

R7 R7a R8 R8a R9 R9a R10 and R10a are each hydrogen.

58. (Withdrawn) The compound of Claim 57 wherein:

V_a is -C(O)-:

 $R^2 is selected from the group consisting of $C_1-C_{12}alkyl, $C_3-C_{12}cycloalkyl,$$ $C_4-C_{12}cycloalkyl, aryl, $C_7-C_{19}aralkyl, C_3-C_{12} heterocyclyl, C_3-C_{12} heterocyclyl, C_3-C_{12} heterocyclylalkyl, aryl, $C_7-C_{19}aralkyl, C_3-C_{12} heterocyclyl, C_3-C_{12} heterocyclylalkyl, aryl, $C_7-C_{19}aralkyl, C_7-C_{19} heterocyclyl, C_7-C_{12} heterocyclyl, C_7-C_{1

C₁-C₁₂heteroaryl and C₃-C₁₂heteroarylalkyl; and

 $R^3 is selected from the group consisting of C_3-C_{12} cycloalkyl, C_4-C_{12} cycloalkylalkyl, aryl, C_7-C_{12} aralkyl, C_3-C_{12} heterocyclyl, C_3-C_{12} heterocyclylalkyl, C_7-C_{12} heteroaryl and C_3-C_{12} heteroarylalkyl. \\$

- 59. (Withdrawn) A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 51.
- (Withdrawn) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 51.
 - 61. (Withdrawn) A compound of formula (la):

wherein:

x and v are each independently 1;

W is $-N(R^1)S(O)_{r}$ (where t is 1 or 2);

 $V is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(S)N(R^1)-, -C(O)O-, -C(S)O-, -S(O)- (where \ tis) \\$

1 or 2), -S(O)_tN(R¹)- (where t is 1 or 2) or -C(R¹¹)H;
each R¹ is independently selected from the group consisting of hydrogen.

C1-C12alkvl, C2-C12hvdroxvalkvl, C4-C12cvcloalkvlalkvl and C7-C19aralkvl;

R2 is selected from the group consisting of C1-C12alkvl, C2-C12alkenvl.

C2-C12hydroxyalkyl, C2-C12hydroxyalkenyl, C2-C12alkoxyalkyl, C3-C12cycloalkyl,

 $C_4-C_{12} \\ \text{cycloalkylalkyl}, \text{ aryl, } C_7-C_{19} \\ \text{aralkyl, } C_3-C_{12} \\ \text{heterocyclyl, } C_3-C_{12} \\ \text{heteroaryl, and } C_3-C_{12} \\ \text{heteroaryl, an$

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 $R^3 \text{ is selected from the group consisting of $C_1\text{-}C_{12}$alkyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$bydroxyalkyl, $C_2\text{-}C_{12}$bydroxyalkenyl, $C_2\text{-}C_{12}$alkexyalkyl, $C_3\text{-}C_{12}$cycloalkyl, $C_4\text{-}C_{12}$cycloalkyl, aryl, $C_7\text{-}C_9$aralkyl, $C_3\text{-}C_{12}$heterocyclyl, $C_3\text{-}C_{12}$heterocyclylalkyl, $C_4\text{-}C_7$cycloalkyl, and $C_3\text{-}C_9$cycloalkyl, $C_4\text{-}C_7$cycloalkyl, $C_4\text{-}C_$

or R³ is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 R^4 , R^5 and R^6 are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or $-N(R^{13})_2$;

 R^7 , R^{7a} , R^8 , R^{8a} , R^9 , R^{9a} , R^{10} , and R^{10a} are each independently selected from hydrogen or C_1 - C_3 alkyl;

R11 is hydrogen or C1-C3alkyl; and

each R¹³ is independently selected from hydrogen or C₁-C₀alkyl; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable

Docket No.: 17243/003001

a stereoisomer, enantiomer or tautomer thereor, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

62. (Withdrawn) The compound of Claim 61 wherein:

x and y are each independently 1;

V is -C(O)- or -C(S)-;

 $R^1 \text{ is hydrogen, } C_1\text{--}C_{12}\text{alkyl, } C_2\text{--}C_{12}\text{hydroxyalkyl, } C_4\text{--}C_{12}\text{cycloalkylalkyl and } C_7\text{--}C_{16}\text{aralkyl; }$

 $R^2 \ is \ selected \ from \ the \ group \ consisting \ of \ C_1-C_{12} alkyl, \ C_2-C_{12} alkenyl, \\ C_2-C_{12} hydroxyalkyl, \ C_2-C_{12} hydroxyalkenyl, \ C_2-C_{12} alkoxyalkyl, \ C_3-C_{12} cycloalkyl, \\ C_4-C_{12} cycloalkylalkyl, \ aryl, \ C_7-C_{19} aralkyl, \ C_3-C_{12} heterocyclyl, \ C_3-C_{12} heterocyclylalkyl, \\ C_1-C_{12} heteroaryl, \ and \ C_3-C_{12} heteroarylalkyl; \\ C_1-C_{12} heteroarylalkyl; \\ C_1-C_{12} heteroaryl, \ and \ C_3-C_{12} heteroarylalkyl; \\ C_1-C_{12} heteroarylalkyl;$

 $R^3 \ is \ selected \ from \ the \ group \ consisting \ of \ C_1-C_{12} alkyl, \ C_2-C_{12} alkenyl,$ $C_2-C_{12}hydroxyalkyl, \ C_2-C_{12}hydroxyalkenyl, \ C_1-C_{12} alkoxy, \ C_2-C_{12} alkoxyalkyl, \ C_3-C_{12} cycloalkyl,$ $C_4-C_{12} cycloalkylalkyl, \ aryl, \ C_7-C_{19} aralkyl, \ C_3-C_{12} heterocyclyl, \ C_3-C_{12} heterocyclylalkyl,$ $C_1-C_{12} heteroaryl \ and \ C_3-C_{12} heteroarylalkyl;$

 R^4 , R^5 and R^6 are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or $-N(R^{19})_2$;

 $R^7,\,R^{7a},\,R^8,\,R^{8a},\,R^9,\,R^{9a},\,R^{10},\,\text{and}\,\,R^{10a}\,\text{are each independently selected from hydrogen or}\,\,C_{1^{\circ}}C_{3}\text{alkyl};\,\text{and}$

each R¹³ is independently selected from hydrogen or C₁-C₈alkyl.

63. (Withdrawn) The compound of Claim 62 wherein:

x and y are each 1;

V is -C(O)-;

R1 is hydrogen, C1-C12alkyl or C4-C12cycloalkylalkyl;

R² is selected from the group consisting of C₁-C₁₂alkyl, C₂-C₁₂alkenyl,

 $C_3\text{--}C_{12}\text{cycloalkyl},\ C_4\text{--}C_{12}\text{cycloalkylalkyl},\ C_7\text{--}C_{19}\text{aralkyl},\ C_3\text{--}C_{12}\text{heterocyclylalkyl} \ \text{and} \ C_3\text{--}C_{13}\text{heteroarylalkyl};$

 R^3 is anyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1 - C_6 clkyl, C_1 - C_6 trihaloalkyl, C_1 - C_6 trihaloalkyl, C_1 - C_6 alkylsulfonyl, $-N(R^{12})_2$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl,

heteroaryl and heteroarylcycloalkyl;

R⁴, R⁵ and R⁶ are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R¹³)₂:

 R^7 , R^{7a} , R^6 , R^{8a} , R^9 , R^{9a} , R^{10} , and R^{10a} are each independently selected from hydrogen or C_1 - C_3 alkyl; and

each R¹³ is independently selected from hydrogen or C₁-C₆alkyl.

64. (Withdrawn) The compound of Claim 63 wherein:

x and y are each 1;

V is -C(O)-;

R1 is hydrogen, C1-C12alkyl or C4-C12cycloalkylalkyl;

R2 is C1-C12alkyl or C2-C12alkenyl;

 R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, $C_1\text{-}C_0\text{ellkyl}$, $C_1\text{-}C_0\text{trihaloalkyl}$, $C_1\text{-}C_0\text{trihaloalkyl}$, $C_1\text{-}C_0\text{trihaloalkyl}$, $C_1\text{-}C_0\text{log}$, $C_1\text{-}C_0\text{log}$, $C_1\text{-}C_0\text{log}$, $C_1\text{-}C_0\text{log}$, $C_1\text{-}C_0\text{log}$, and $-S(O)_2\text{N}(R^{12})_2$, and $-S(O)_2\text{N}(R^{12})_2$.

 \mbox{R}^4,\mbox{R}^5 and \mbox{R}^8 are each independently selected from hydrogen, bromo, fluoro or chloro; and

R⁷, R^{7a}, R⁸, R^{8a}, R⁹, R^{9a}, R¹⁰ and R^{10a} are each hydrogen.

65. (Withdrawn) The compoundof Claim 63 wherein:

x and y are each 1;

V is -C(O)-:

R1 is hydrogen, C1-C12alkyl or C4-C12cycloalkylalkyl;

R2 is C2-C12cvcloalkyl or C4-C12cvcloalkylalkyl:

R³ is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C₁-C₆alkyl, C₁-C₆trihaloalkyl, C₁-C₆trihaloalkyl, C₁-C₆trihaloalkoxy, C₁-C₆alkylsulfonyl, -N(R¹²)₂, -OC(O)R¹², -C(O)OR¹² and -S(O)₂N(R¹²)₂;

 \mbox{R}^4,\mbox{R}^5 and \mbox{R}^8 are each independently selected from hydrogen, bromo, fluoro or chloro; and

 $\mathsf{R}^7,\,\mathsf{R}^{7a},\,\mathsf{R}^8,\,\mathsf{R}^{8a},\,\mathsf{R}^9,\,\mathsf{R}^{9a},\,\mathsf{R}^{10}$ and R^{10a} are each hydrogen.

66. (Withdrawn) The compound of Claim 65 wherein:

R2 is C4-C12cycloalkylalkyl;

R³ is phenyl optionally substituted by one or more substituents selected from halo. C₁-C₆alkyl. C₁-C₆trihaloalkyl and C₁-C₆trihaloalkoxy;

R4 and R6 are both hydrogen; and

R⁵ is hydrogen or bromo.

67. (Withdrawn) The compound of Claim 66 selected from the group consisting of the following:

5-Bromo-6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridine-3-sulfonic acid (2-

cyclopropylethyl)amide; and

6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]pyridine-3-sulfonic acid (2-

cyclopropylethyl)amide.

68. (Withdrawn) The compound of Claim 63 wherein:

x and y are each 1;

V is -C(O)-;

R1 is hydrogen, C1-C12alkyl or C4-C12cycloaikylalkyl;

R2 is C7-C19 aralkyl, C3-C12 heterocyclylalkyl or C3-C12 heteroarylalkyl;

 R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 trihaloalkyl, C_1 - C_6 trihaloalkoxy, C_1 - C_6 alkylsulfonyl, $-N(R^{12})_2$, $-OC(O)R^{12}$, $-C(O)OR^{12}$ and $-S(O)_2N(R^{12})_2$;

 $$\rm R^4,\,R^5$ and $\rm R^6$ are each independently selected from hydrogen, bromo, fluoro or chloro; and

$$\mathsf{R}^7,\,\mathsf{R}^{7a},\,\mathsf{R}^8,\,\mathsf{R}^{8a},\,\mathsf{R}^9,\,\mathsf{R}^{9a},\,\mathsf{R}^{10},$$
 and R^{10a} are each hydrogen.

69. (Withdrawn) A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 61.

70. (Withdrawn) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 61.